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Stevens-Johnson syndrome (SJS) is a mucocutaneous reaction typically brought on by medications 
or infections. The diagnosis of SJS is typically made when patients present with a variable appearing 
rash and involvement of the oral, ocular, or genital mucosa. However, there are rare reports 
of atypical or incomplete SJS. These cases are usually associated with children infected with 
Mycoplasma pneumoniae, which presents with severe mucositis but no rash. Herein, we report the 
first case of adult incomplete SJS brought on by sulfonamide antimicrobial use without clinical or 
laboratory evidence of M. pneumoniae infection. [Clin Pract Cases Emerg Med. 2019;3(3):240-242.]   
INTRODUCTION
Stevens-Johnson syndrome (SJS) is a rare, mucocutaneous 
reaction that affects two to seven per million people per year and 
is often precipitated by medications and infections.1 Women, 
human immunodeficiency virus-infected patients, and those 
with cancer are disproportionately affected.2,3 It is characterized 
by skin rash and the involvement of the oral mucosa, genitals, 
or conjunctivae, but rare presentations of incomplete SJS are 
reported in children after Mycoplasma pneumoniae infection.4 
Here, we report the first case of oral and ocular SJS without 
skin lesions in a healthy adult after exposure to an antibacterial 
sulfonamide without M. pneumoniae infection. 
CASE REPORT
A 25-year-old African-American male with a history of 
diabetes presented to our emergency department (ED) with eye 
irritation, painful mouth sores, and difficulty swallowing. Three 
weeks prior to this visit, he was seen at a local ED for a small 
abscess on the posterior neck and treated with a 10-day course of 
trimethoprim/sulfamethoxazole (TMP-SMX). He did not begin 
this antibiotic for three days and took it intermittently over the 
next three weeks. He returned to the local ED two weeks after the 
first visit for symptoms of sore throat and lip swelling. This was 
attributed to a food allergy, and he was discharged with a five-
day course of prednisone. He returned to the same institution two 
days later with worsening lip swelling and new mouth sores. He 
was prescribed nystatin suspension for presumed oral candidiasis 
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that he took with the prednisone and remaining TMP-SMX for 
two days prior to arriving at our ED.
He arrived at our institution with two remaining tablets 
of TMP-SMX and complaining of worsening lip swelling, 
mouth sores, eye irritation, and difficulty swallowing over 
the two days since his last visit to the local ED. Vital signs 
on presentation were a temperature of 38.6 degrees Celsius, 
blood pressure 132/73 millimeters of mercury, heart rate 
115 beats per minute, respiratory rate 16 breaths per minute, 
and pulse oximetry 99% on room air. His review of systems 
was positive for odynophagia, sore throat, and eye irritation; 
negative for cough, rash, joint pain, or genital irritation. 
Physical examination showed injected conjunctiva bilaterally 
with sloughing (Image 1); visual acuity was intact. The mouth 
Image 1. Injected conjunctiva with epithelial sloughing. Patient 
consent was given to use this photo.
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What do we already know about this clinical 
entity? 
Rare cases of incomplete Stevens-Johnson 
syndrome having only mucositis without 
rash occur in children infected with 
Mycoplasma pneumoniae. 
What makes this presentation of disease 
reportable? 
We report the first case of oral and ocular 
SJS without skin lesions in a healthy 
adult after exposure to an antibacterial 
sulfonamide and without Mycoplasma 
pneumoniae infection. 
What is the major learning point? 
Pay careful attention to new or recently 
completed medications in patients 
complaining of skin or isolated mucous 
membrane complaints.
How might this improve emergency 
medicine practice? 
Awareness that incomplete Stevens-
Johnson syndrome can occur in adults 
as well as children will help clinicians 
identify precipitating agents and avoid 
delays in diagnosis.
with M. pneumoniae being the most common infectious agent 
associated with SJS among all age groups.5
Mucositis without skin involvement is an extremely rare 
variation of SJS most often seen in children infected by M. 
pneumoniae.4,7 Isolated mucositis is also a rare complication 
associated with combining TMP-SMX and methotrexate.8 
However, our case is the first reported instance of isolated 
mucositis in an adult, brought on by a single medication 
known to cause SJS without clinical or laboratory evidence 
of M. pneumoniae infection. While some authors feel these 
atypical or incomplete presentations of SJS represent a 
distinct clinical entity, a common immunologic mechanism 
involving interleuken-15 and cluster of differentiation 8+ 
cytotoxic T cell-induced apoptosis of keratinocytes is likely 
common to all forms of SJS.9
Multiple outpatient visits were required in this 
case to establish the correct diagnosis. Additionally, we Image 2. Severe stomatitis with diffuse ulcerations.
and pharynx had severe stomatitis with ulcers involving the 
lips, tongue, buccal mucosa, and oropharyngeal mucosa 
(Image 2). There were no skin rashes and the lesion on his 
neck was well healed. All images were taken and published 
with the express, written consent of the patient. 
Laboratory investigation revealed negative gonococcus/
chlamydia polymerase chain reaction and negative M. 
pneumoniae immunoglobulin M on immunofluorescence 
assay. He was treated with intravenous (IV) fluids and 
admitted to the hospital for ophthalmologic and dermatologic 
consultations. The previously prescribed TMP-SMX was 
discontinued. He received IV methylprednisolone and 
mixed medication mouthwash for his stomatitis. The mild 
conjunctival sloughing was treated with erythromycin 
ophthalmic ointment, prednisolone acetate ophthalmic drops, 
and artificial tears, but did not require amniotic membrane 
graft. He was discharged after two days on a prednisone 
taper, prednisolone ophthalmic drops, and erythromycin 
ophthalmic ointment. 
DISCUSSION
SJS is part of a spectrum of mucocutaneous diseases 
affecting the skin and mucous membranes, which include 
erythema multiforme minor, SJS (erythema multiforme major), 
and toxic epidermal necrolysis.5 Skin involvement occurs in 
more than 90% of patients, but the appearance of skin lesions 
can vary from targetoid to diffuse erythema.6 Mucosal lesions 
typically occur at multiple sites such as the mouth, eyes, or 
genitalia. In adults, medications such as aromatic antiepileptics, 
allopurinol, sulfonamides, and nonsteroidal anti-inflammatory 
drugs are the most common precipitants.5,6 Bacterial and viral 
infections are the most commonly identified cause in children, 
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were assisted by obvious vital sign abnormalities and 
symptoms that precluded discharge. Careful attention to 
new or recently completed medications will often provide 
diagnostic clues to help make such a difficult diagnosis. In 
this case, the diagnosis was made when the provider found 
the bottle of TMP-SMX in the patient’s medication bag.
Treatment of SJS is largely supportive and includes 
removal of any offending medications. Corticosteroids, 
cyclosporine, IV immunoglobulin, plasmapheresis, and tumor 
necrosis factor inhibitors have all been used.10, 11 There is no 
clear benefit to any pharmacologic strategy, and treatments 
should be individualized based on severity and timing of the 
symptoms. Patients with severe conjunctival sloughing should 
receive amniotic membrane grafting early in their disease to 
preserve visual acuity.12 Our patient improved with removal of 
the offending antibiotic and steroids. He was advised to avoid 
other antimicrobial sulfonamides.
Documented patient informed consent and/or Institutional Review 
Board approval has been obtained and filed for publication of this 
case report.
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